1. Home
  2. SLE vs NGEN Comparison

SLE vs NGEN Comparison

Compare SLE & NGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Super League Enterprise Inc.

SLE

Super League Enterprise Inc.

HOLD

Current Price

$3.86

Market Cap

177.4M

ML Signal

HOLD

Logo NervGen Pharma Corp. Common stock

NGEN

NervGen Pharma Corp. Common stock

N/A

Current Price

$2.28

Market Cap

200.0M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
SLE
NGEN
Founded
2014
2017
Country
United States
Canada
Employees
34
N/A
Industry
Services-Misc. Amusement & Recreation
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
177.4M
200.0M
IPO Year
2019
2018

Fundamental Metrics

Financial Performance
Metric
SLE
NGEN
Price
$3.86
$2.28
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
1
Target Price
$60.00
$18.00
AVG Volume (30 Days)
1.9M
457.8K
Earning Date
05-14-2026
04-02-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,064,000.00
N/A
Revenue This Year
$24.86
N/A
Revenue Next Year
$49.77
N/A
P/E Ratio
N/A
N/A
Revenue Growth
90.41
N/A
52 Week Low
$0.48
$1.58
52 Week High
$11.43
$5.93

Technical Indicators

Market Signals
Indicator
SLE
NGEN
Relative Strength Index (RSI) 53.69 80.28
Support Level $2.89 $1.62
Resistance Level $4.89 $4.44
Average True Range (ATR) 0.83 0.12
MACD 0.02 0.08
Stochastic Oscillator 33.52 92.21

Price Performance

Historical Comparison
SLE
NGEN

About SLE Super League Enterprise Inc.

Super League Enterprise Inc connects brands with the gaming population of around 3.5 billion through advertising and branded content programs across gaming and digital media platforms. The Company generates revenue by delivering these programs through proprietary interactive formats, creator content, immersive experiences, data-driven insights, and strategic campaign services designed to improve marketing performance. By translating player behavior into actionable intelligence, Super League serves as a trusted partner helping brands reach and influence consumers who play video games. With a deep understanding of this engaged yet under-monetized audience, it is positioned to capture an increasing share of brand advertising spend as the market evolves.

About NGEN NervGen Pharma Corp. Common stock

NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.

Share on Social Networks: